Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Inclusion Criteria

• •All Participants:
• •of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug
• •must not have consumed grapefruit or grapefruit juice within 7 days of Day -1 and throughout the study
• •HCV Participants:
• •documented clinical history compatible with chronic hepatitis C.
• •have not received direct-acting antiviral treatment for hepatitis C infection
• •has HCV Genotype 1, 2, 3, 4, 5 or 6